C. Chien

发表

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (B

N. Meanwell, D. Langley, R. Colonno, 2013, Journal of medicinal chemistry.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

Min Gao, Nicholas A. Meanwell, Lawrence G. Hamann, 2010, Nature.

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model

M. Monshouwer, D. Ouellet, L. D. De Zwart, 2020, Clinical Pharmacokinetics.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 6. Preclinical and human pharmacokinetic profiling of BMS-663749, a phosphonooxymethyl prodrug of the HIV-1 attachment inhibitor 2-(4-benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043)

N. Meanwell, R. Colonno, K. Yeung, 2012, Journal of medicinal chemistry.

Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy

R. Thurmond, M. Genovese, Carol F. Franks, 2015, The Journal of Rheumatology.

An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer

F. Saad, R. de Wit, W. Edenfield, 2018, Cancer Chemotherapy and Pharmacology.

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

V. Ribrag, C. D. de Boer, F. Morschhauser, 2015, Clinical Cancer Research.

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer

C. Kollmannsberger, K. Chi, T. Griffin, 2015, Journal of clinical pharmacology.

Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects

J. Pérez-Ruixo, D. Ouellet, O. Ackaert, 2019, Clinical Pharmacokinetics.

Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes

F. Jacobs, J. Snoeys, R. de Vries, 2019, Drug Metabolism and Disposition.

HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer

S. Upadhyay, W. Figg, P. Mendiratta, 2018, The Journal of clinical investigation.

Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study

F. Saad, E. Posadas, M. D. de Jonge, 2020, Clinical Cancer Research.

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

M. Krystal, R. Bertz, D. Grasela, 2012, The Journal of infectious diseases.

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer

J. Carles, I. Durán, J. Jiao, 2020, Clinical Pharmacokinetics.

Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.

D. Grasela, P. Timmins, A. Dennis, 2013, Journal of pharmaceutical sciences.

Effect of food on abiraterone pharmacokinetics: a review

Caly Chien, M. Smith, Michael Smith, 2017 .

In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity

J. Snoeys, A. Bernard, J. Jiao, 2016, Drug Metabolism and Disposition.

IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES TO ASSESS THE EFFECT OF ABIRATERONE ACETATE , ABIRATERONE , AND METABOLITES OF ABIRATERONE ON CYP 2 C 8 ACTIVITYa

J. Snoeys, A. Bernard, J. Jiao, 2016 .

Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicin

A. Bernard, N. Vaccaro, M. Acharya, 2015, Clinical pharmacology in drug development.

Single‐dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment

T. Marbury, C. Haqq, E. Lawitz, 2014, Journal of clinical pharmacology.

Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing

A. Bernard, N. Vaccaro, J. Jiao, 2014, Cancer Chemotherapy and Pharmacology.

Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study

N. Agarwal, O. Ackaert, S. Chowdhury, 2022, Cancer Chemotherapy and Pharmacology.

Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.

F. Saad, E. Posadas, T. Friedlander, 2017 .

FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.

J. Tabernero, T. Yoshino, A. Dasari, 2021, Future oncology.

In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity

J. Snoeys, J. Jiao, J. Monbaliu, 2016, Drug Metabolism and Disposition.

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors

G. Falchook, A. Dasari, E. Hamilton, 2023, Investigational New Drugs.

Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

M. Krystal, R. Bertz, D. Grasela, 2012, The Journal of infectious diseases.

Pharmaceutics, Drug Delivery and Pharmaceutical Technology Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug

D. Grasela, P. Timmins, A. Dennis, 2013 .

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.

Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

E. Small, J. Pérez-Ruixo, D. Ouellet, 2020, Clinical Cancer Research.